Lilly Migraine Med's Uncertain Future Kills Teva's Patent Suit
A Massachusetts federal judge on Thursday cleared Eli Lilly and Co. from allegations that it infringed nine Teva Pharmaceuticals patents by preparing to launch a new migraine biologic, finding the suit is premature...To view the full article, register now.
Already a subscriber? Click here to view full article